$313 Billion is the total value of Versant Venture Management, LLC's 8 reported holdings in Q1 2018. The portfolio turnover from Q4 2017 to Q1 2018 was 14.3% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| CRSP | New | CRISPR Therapeutics AG | $210,551,322,000 | – | 4,606,242 | +100.0% | 67.34% | – |
| BOLD | Audentes Therapeutics, Inc. | $36,198,681,000 | -3.8% | 1,204,615 | 0.0% | 11.58% | -70.8% | |
| AKAOQ | Achaogen, Inc. | $16,590,918,000 | +20.6% | 1,281,152 | 0.0% | 5.31% | -63.4% | |
| OCUL | Ocular Therapeutix, Inc. | $14,422,150,000 | +46.3% | 2,215,384 | 0.0% | 4.61% | -55.5% | |
| CBAY | CymaBay Therapeutics, Inc. | $13,621,327,000 | +41.2% | 1,048,601 | 0.0% | 4.36% | -57.1% | |
| EYES | Second Sight Medical Products, Inc. | $8,626,512,000 | +0.5% | 4,492,975 | 0.0% | 2.76% | -69.4% | |
| IMDZ | ImmuneDesign Corp. | $7,287,093,000 | -15.4% | 2,208,210 | 0.0% | 2.33% | -74.3% | |
| CLVS | Clovis Oncology, Inc. | $5,377,944,000 | -22.4% | 101,855 | 0.0% | 1.72% | -76.4% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-05-03
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| CymaBay Therapeutics, Inc. | 35 | Q2 2023 | 10.2% |
| Clovis Oncology, Inc. | 32 | Q3 2022 | 53.2% |
| CRISPR Therapeutics AG | 23 | Q3 2023 | 77.2% |
| Ocular Therapeutix, Inc. | 22 | Q4 2020 | 18.0% |
| Gritstone Oncology, Inc. | 18 | Q3 2023 | 25.4% |
| Achaogen, Inc. | 18 | Q1 2019 | 23.5% |
| Adverum Biotechnologies, Inc. | 15 | Q3 2023 | 21.0% |
| Second Sight Medical Products, Inc. | 15 | Q3 2020 | 9.0% |
| Audentes Therapeutics, Inc. | 13 | Q3 2019 | 39.6% |
| Aligos Therapeutics, Inc. | 12 | Q3 2023 | 15.7% |
View Versant Venture Management, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-08 |
| 13F-HR | 2023-11-03 |
| 13F-HR | 2023-08-09 |
| 13F-HR | 2023-05-11 |
| 144 | 2023-04-20 |
| 13F-HR | 2023-02-09 |
| 13F-HR | 2022-11-10 |
| 13F-HR | 2022-08-11 |
| 13F-HR | 2022-05-10 |
| 13F-HR | 2022-02-11 |
View Versant Venture Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.